192 related articles for article (PubMed ID: 32578360)
1. USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines.
Wang H; Meng Q; Ding Y; Xiong M; Zhu M; Yang Y; Su H; Gu L; Xu Y; Shi L; Zhou H; Zhang N
FEBS J; 2021 Feb; 288(4):1325-1342. PubMed ID: 32578360
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of potent USP28 inhibitors derived from Vismodegib.
Zhou D; Xu Z; Huang Y; Wang H; Zhu X; Zhang W; Song W; Gao T; Liu T; Wang M; Shi L; Zhang N; Xiong B
Eur J Med Chem; 2023 Jun; 254():115369. PubMed ID: 37075624
[TBL] [Abstract][Full Text] [Related]
3. Otilonium Bromide acts as a selective USP28 inhibitor and exhibits cytotoxic activity against multiple human cancer cell lines.
Xu Z; Wang H; Meng Q; Ding Y; Zhu M; Zhou H; Zhang N; Shi L
Biochem Pharmacol; 2023 Sep; 215():115746. PubMed ID: 37579857
[TBL] [Abstract][Full Text] [Related]
4. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
5. Differential Oligomerization of the Deubiquitinases USP25 and USP28 Regulates Their Activities.
Sauer F; Klemm T; Kollampally RB; Tessmer I; Nair RK; Popov N; Kisker C
Mol Cell; 2019 May; 74(3):421-435.e10. PubMed ID: 30926243
[TBL] [Abstract][Full Text] [Related]
6. Distinct USP25 and USP28 Oligomerization States Regulate Deubiquitinating Activity.
Gersch M; Wagstaff JL; Toms AV; Graves B; Freund SMV; Komander D
Mol Cell; 2019 May; 74(3):436-451.e7. PubMed ID: 30926242
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
Abidi A
Indian J Pharmacol; 2014; 46(1):3-12. PubMed ID: 24550577
[TBL] [Abstract][Full Text] [Related]
8. Computational approach to target USP28 for regulating Myc.
Chakravorty D; Ghosh A; Saha S
Comput Biol Chem; 2020 Apr; 85():107208. PubMed ID: 32028107
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
11. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer.
Diefenbacher ME; Popov N; Blake SM; Schülein-Völk C; Nye E; Spencer-Dene B; Jaenicke LA; Eilers M; Behrens A
J Clin Invest; 2014 Aug; 124(8):3407-18. PubMed ID: 24960159
[TBL] [Abstract][Full Text] [Related]
12. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
Dirix L; Rutten A
Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib: a review.
Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
[TBL] [Abstract][Full Text] [Related]
14. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.
Liao S; Floyd C; Verratti N; Leung L; Wu C
Life Sci; 2020 Mar; 244():117302. PubMed ID: 31953165
[TBL] [Abstract][Full Text] [Related]
15. USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma.
Prieto-Garcia C; Tomašković I; Shah VJ; Dikic I; Diefenbacher M
Cells; 2021 Oct; 10(10):. PubMed ID: 34685632
[TBL] [Abstract][Full Text] [Related]
16. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
18. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
19. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
[TBL] [Abstract][Full Text] [Related]
20. Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily.
Wrigley JD; Gavory G; Simpson I; Preston M; Plant H; Bradley J; Goeppert AU; Rozycka E; Davies G; Walsh J; Valentine A; McClelland K; Odrzywol KE; Renshaw J; Boros J; Tart J; Leach L; Nowak T; Ward RA; Harrison T; Andrews DM
ACS Chem Biol; 2017 Dec; 12(12):3113-3125. PubMed ID: 29131570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
